It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
originally posted by: Phage
a reply to: AdmireTheDistance
The OpEd in the OP says that nicotine is the ticket. Use the patch.
If one's good, two are better.
originally posted by: Phage
a reply to: AlienView
What consensus? An OpEd is not consensus.
Still no link to the study mentioned in your title?
First peer reviewed study to show Nicotine offers potential protection against Covid 19
VERDICT
There are biologically plausible pathways through which nicotine may impact SARS-CoV-2, but the clinical significance of these is entirely unclear.
BACKGROUND
There is mixed evidence on the role of smoking in COVID-19 infection and associated outcomes. Whereas the expectation is that smoking would predispose to worse outcomes from COVID-19, as is the case in other acute respiratory infections, some (but not all) studies of COVID-19 have detected fewer people who smoke than would be expected in hospitalised patients with COVID-19. It is unclear whether this is due to biases, confounding, misreporting, or a potential protective effect of smoking on COVID-19 outcomes. Irrespective of COVID-19, smoking is uniquely deadly. However, nicotine, the addictive component of cigarettes, can be safe when used in other forms, and there is some biological plausibility regarding a possible role of nicotine in COVID-19 infection. Below we briefly review evidence to date on the role of nicotine in COVID-19. This is important to people who smoke, but it could also be of general relevance, as some have hypothesised nicotine may be a potential treatment for COVID-
CURRENT EVIDENCE
We searched the literature for studies relating to COVID-19 and nicotine. Some are underway, and this piece will be updated as new findings emerge. In the meantime, the available research literature is mainly in the form of speculative commentaries, with some lab studies also reported.
Commentaries regarding nicotine and COVID-19 all agree nicotine potentially has a role to play based on its role in the renin-angiotensin system. In particular, nicotine can impact the angiotensin-converting enzyme (ACE) 2, which is relevant because coronaviruses bind to ACE2. However, some authors interpret this as suggesting nicotine is likely to be harmful in the context of COVID-19, and others suggest the opposite.
Disclaimer: the article has not been peer-reviewed; it should not replace individual clinical judgement and the sources cited should be checked. The views expressed in this commentary represent the views of the authors and not necessarily those of the host institution, the NHS, the NIHR, or the Department of Health and Social Care. The views are not a substiute for professional medical advice.
It doesn't surprise me that the studies are hard to find.
I wouldn't suggest anything. The claim was:
Would you suggest a hoax, actually several hoaxes, since they are
First peer reviewed study to show Nicotine offers potential protection against Covid 19
originally posted by: LeoStarchild
a reply to: SaturnFX
True but cigs dont blow up in your face.
Ive never been keen with replacing a thorn with another thorn
**had a checkup the other day, and i smoke about 1-1.5 a day. They said 110 healhty
Abstract
The effects of smoking on Corona Virus Disease 2019 (COVID-19) are currently unknown. The purpose of this study was to systematically examine the prevalence of current smoking among hospitalized patients with COVID-19 in China, considering the high-population smoking prevalence in China (26.6%). A systematic review of the literature (PubMed) was performed on April 1. Thirteen studies examining the clinical characteristics of hospitalized COVID-19 patients in China and presenting data on the smoking status were found. The pooled prevalence of current smoking from all studies was calculated by random-effect meta-analysis. To address the possibility that some smokers had quit shortly before hospitalization and were classified as former smokers on admission to the hospital, we performed a secondary analysis in which all former smokers were classified as current smokers. A total of 5960 patients were included in the studies identified. The current smoking prevalence ranged from 1.4% (95% CI 0.0–3.4%) to 12.6% (95% CI 10.6–14.6%). An unusually low prevalence of current smoking was observed from the pooled analysis (6.5%, 95% CI 4.9–8.2%) as compared to population smoking prevalence in China. The secondary analysis, classifying former smokers as current smokers, found a pooled estimate of 7.3% (95% CI 5.7–8.9%). In conclusion, an unexpectedly low prevalence of current smoking was observed among patients with COVID-19 in China, which was approximately 1/4th the population smoking prevalence. Although the generalized advice to quit smoking as a measure to reduce health risk remains valid, the findings, together with the well-established immunomodulatory effects of nicotine, suggest that pharmaceutical nicotine should be considered as a potential treatment option in COVID-19.
Internal and Emergency Medicine is an independent, international journal devoted to all topics related to science and practice of internal and emergency medicine and designed for internists and emergency physicians. The Journal publishes Original articles, Review articles, Letters to the Editor, Editorials and Commentaries and it encourages letters of rebuttal and criticism of published articles.
Sort of different from the claim of the OP.
This preliminary analysis, assuming that the reported data are accurate, suggests that current smoking does not appear to be a predisposing factor for hospitalization for COVID-19.